Richard A. Heyman, Director at Enliven Therapeutics, Inc. (ELVN), sold 4,280 shares at $13.00 ($56K) on 2023-12-19, disclosed to the SEC on 2023-12-21.
Scheduled sale ($56k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $13.00 | 255 | $3K | 5.9% |
| 2 | $13.02 | 1,915 | $25K | 44.7% |
| 3 | $13.02 | 2,110 | $27K | 49.3% |
| Total | $13.02 avg | 4,280 | $56K | 100% |
| Filing → |
| ELVN | SELL | 2026-02-19 | $32K | — | Filing → |
| ELVN | SELL | 2026-01-22 | $33K | — | Filing → |
| ORIC | SELL | 2026-01-20 | $80K | — | Filing → |